Onternabez: Difference between revisions
Content deleted Content added
No edit summary |
|||
| Line 66: | Line 66: | ||
| last8= Gao | first8= B. |
| last8= Gao | first8= B. |
||
| last9= Pacher | first9= P. |title= Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis |journal= Journal of leukocyte biology |volume= 82 |issue= 6 |pages= 1382–1389 |year= 2007 |pmid= 17652447 |doi= 10.1189/jlb.0307180 |pmc= 2225476 }} |
| last9= Pacher | first9= P. |title= Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis |journal= Journal of leukocyte biology |volume= 82 |issue= 6 |pages= 1382–1389 |year= 2007 |pmid= 17652447 |doi= 10.1189/jlb.0307180 |pmc= 2225476 }} |
||
</ref><ref>{{Cite journal |author= Rajesh, M.|title= CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion |journal= |
</ref><ref>{{Cite journal |author= Rajesh, M.|title= CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion |journal=American Journal of Physiology. Heart and Circulatory Physiology |volume= 293 |issue= 4 |pages= H2210–H2218 |year= 2007 |pmid= 17660390 |doi= 10.1152/ajpheart.00688.2007 |pmc= 2229632 |display-authors=etal}} |
||
</ref> |
</ref> |
||
Revision as of 02:13, 15 February 2016
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H43O3 |
| Molar mass | 415.63 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
  (what is this?) (verify) | |
HU-308 is a drug that acts as a cannabinoid agonist. It is highly selective for the CB2 receptor subtype, with a selectivity of over 5000x for CB2 vs CB1.[1] The synthesis and characterization took place in the laboratory of Prof. Mechoulam at the Hebrew University of Jerusalem in the late 1990s. It has analgesic effects,[2] promotes proliferation of neural stem cells,[3] and protects both liver and blood vessel tissues against oxidative stress via inhibition of TNF-α.[4][5]
Legal status
United States
HU-308 is not scheduled at the federal level in the United States.[6]
Florida
"HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[7]
See also
References
- ^ Hanus, L.; et al. (1999). "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor". Proceedings of the National Academy of Sciences of the United States of America. 96 (25): 14228–14233. Bibcode:1999PNAS...9614228H. doi:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.
- ^ Labuda, C.; Koblish, M.; Little, P. (2005). "Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain". European Journal of Pharmacology. 527 (1–3): 172–174. doi:10.1016/j.ejphar.2005.10.020. PMID 16316653.
- ^ Palazuelos, J.; et al. (2006). "Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation". The FASEB Journal. 20 (13): 2405–2407. doi:10.1096/fj.06-6164fje. PMID 17015409.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Batkai, S.; Osei-Hyiaman, D.; Hasko, G.; Liaudet, L.; Gao, B.; Pacher, P. (2007). "Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis". Journal of leukocyte biology. 82 (6): 1382–1389. doi:10.1189/jlb.0307180. PMC 2225476. PMID 17652447.
- ^ Rajesh, M.; et al. (2007). "CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion". American Journal of Physiology. Heart and Circulatory Physiology. 293 (4): H2210 – H2218. doi:10.1152/ajpheart.00688.2007. PMC 2229632. PMID 17660390.
- ^ 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.
- ^ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |